Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Total Liabilities : €254.9 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi Total Liabilities?

Laboratorios Farmaceuticos Rovi's Total Liabilities for the quarter that ended in Mar. 2024 was €254.9 Mil.

Laboratorios Farmaceuticos Rovi's quarterly Total Liabilities declined from Sep. 2023 (€276.09 Mil) to Dec. 2023 (€256.39 Mil) and declined from Dec. 2023 (€256.39 Mil) to Mar. 2024 (€254.88 Mil).

Laboratorios Farmaceuticos Rovi's annual Total Liabilities increased from Dec. 2021 (€261.70 Mil) to Dec. 2022 (€357.32 Mil) but then declined from Dec. 2022 (€357.32 Mil) to Dec. 2023 (€256.39 Mil).

Laboratorios Farmaceuticos Rovi Total Liabilities Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi Total Liabilities Chart

Laboratorios Farmaceuticos Rovi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

188.83

200.74

261.70

357.32

256.39

Laboratorios Farmaceuticos Rovi Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															316.40	380.05	276.09	256.39	254.88

Laboratorios Farmaceuticos Rovi Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Laboratorios Farmaceuticos Rovi's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	199.843	+	(52.242	+	4.305
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	256.4

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	799.884	-	543.494
	=	256.4

Laboratorios Farmaceuticos Rovi's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	191.246	+	(59.628	+	4.007
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	254.9

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	778.663	-	523.782
	=	254.9

Laboratorios Farmaceuticos Rovi Total Liabilities Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ROVI:Mexico ROVIe:UK 41L:Germany

Address

Julian Camarillo, 35, Madrid, ESP, 28037

Website

https://www.rovi.es

Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.